Healing · research peptide
Studied for: tissue repair, wound healing, gastrointestinal protection (preclinical)
Body Protection Compound 157 is a synthetic pentadecapeptide derived from a protective protein identified in human gastric juice. It has been studied primarily in rodent and cell models for tissue-repair signaling through VEGFR2, focal-adhesion kinase (FAK) / paxillin, and JAK-2. There is no published human pharmacokinetic study and it is not FDA-approved.
BPC-157 (Body Protection Compound 157; also referenced in patent literature as PL 14736) is a synthetic 15-amino-acid peptide corresponding to a partial sequence of a protein originally isolated from human gastric juice.[1] In preclinical literature it is described as a "cytoprotective" peptide with effects on tissue repair, angiogenesis, and gut-axis signaling observed across a broad range of injury models.[1][2] Its most-studied downstream effects cluster around wound healing and gastrointestinal protection; human clinical data remains limited.
Across published preclinical work, three converging pathways are described:
Reviews have additionally described effects on the brain–gut axis, nitric-oxide signaling, and dopaminergic/serotonergic modulation in animal models.[2] These remain preclinical findings.
A 2022 pharmacokinetic study in rats and beagle dogs by Xu et al. reported an elimination half-life of less than 30 minutes after single and repeat intravenous and intramuscular administration, with linear pharmacokinetic behavior across the tested dose range.[3] Reported absolute bioavailability by the intramuscular route was approximately 14–19% in rats and 45–51% in dogs. Distribution and excretion data are available in the same paper.
No peer-reviewed human pharmacokinetic study has been published as of this page's review date. Claims about subcutaneous half-life in humans are not supported by published data and should be treated as inference.
Reconstitution is arithmetic, not medicine. The amount of bacteriostatic water you add to the vial determines the concentration. The concentration determines how many units on an insulin syringe equal a given mcg amount. Nothing about this arithmetic recommends a dose.
Two people reconstituting the same vial can draw different unit counts for the same mcg dose — the only thing that matters is the ratio of mass in the vial to volume of diluent added. Record the concentration you used; the app will persist it per vial so math on the next draw stays consistent.
There is no single correct amount. A common choice is 2 mL of bacteriostatic water, producing a 2.5 mg/mL concentration — 10 units per 250 mcg. Using 3 mL gives ~15 units per 250 mcg. Using 5 mL gives 25 units per 250 mcg. The volume is a choice about how many units you want to draw per dose; it does not change the total drug in the vial.
With 5 mg in 2 mL: 10 units. With 5 mg in 3 mL: about 15 units. With 10 mg in 2 mL: 5 units. The answer depends entirely on the concentration after reconstitution.
Published rat and beagle dog pharmacokinetic data reports an elimination half-life of less than 30 minutes after IV and IM dosing.[3] No peer-reviewed human half-life has been published.
Refrigerated at 2–8 °C. Bacteriostatic water (0.9% benzyl alcohol) permits multi-draw use with sterile technique; sterile water is typically reserved for single-draw preparations. Discard cloudy or discolored solutions.
No. BPC-157 is not FDA-approved for any clinical indication. FDA's April 15, 2026 503A categories update listed BPC-157 in Category 2 while noting removal after seven calendar days because nominations were withdrawn, with FDA intending to consult PCAC on BPC-157-related substances on July 23, 2026.[5] This page does not recommend doses or acquisition channels.
Because "units" on an insulin syringe measures volume, not mass (1 unit = 0.01 mL on a 100-unit syringe). The mcg per unit is determined by your reconstitution concentration. Two people with the same 5 mg vial can correctly draw different unit counts for the same mcg dose.
Enhanced Health keeps peptide protocols, vial concentrations, dose history, and lab context in one iPhone app. Local-first. No ads. Research/educational framing throughout.